Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
283.05B
Market cap283.05B
Price-Earnings ratio
20.65
Price-Earnings ratio20.65
Dividend yield
2.24%
Dividend yield2.24%
Average volume
2.88M
Average volume2.88M
High today
$139.45
High today$139.45
Low today
$137.58
Low today$137.58
Open price
$138.16
Open price$138.16
Volume
923.10K
Volume923.10K
52 Week high
$170.46
52 Week high$170.46
52 Week low
$121.57
52 Week low$121.57

NVS News

Bloomberg 2h
Novartis Heart Drug Failure Rattles Market for Rival Treatments - Bloomberg.com

...

Novartis Heart Drug Failure Rattles Market for Rival Treatments - Bloomberg.com
TipRanks 6h
Novartis downgraded to Hold from Buy at Deutsche Bank

Deutsche Bank analyst Emmanuel Papadakis last night downgraded Novartis (NVS) to Hold from Buy with a price target of CHF 120, down from CHF 140. The firm cites...

TipRanks 18h
Dyne Therapeutics downgraded to Underweight from Neutral at JPMorgan

JPMorgan analyst Tessa Romero downgraded Dyne Therapeutics (DYN) to Underweight from Neutral with a price target of $10, down from $17. The firm believes Novart...

Analyst ratings

50%

of 30 ratings
Buy
36.7%
Hold
50%
Sell
13.3%

More NVS News

TipRanks 18h
Novartis initiated with a Sector Perform at RBC Capital

RBC Capital initiated coverage of Novartis (NVS) with a Sector Perform rating and CHF 120 price target The unexpected pelacarsen failure and del-desiran DM1 set...

TipRanks 21h
Eli Lilly Stock Falls on News of Competitor Novartis’ Cholesterol Drug Setback

Eli Lilly’s (LLY) stock is down 2% on reports that rival Novartis’ (NVS) new cholesterol drug failed a closely watched cardiovascular trial. The failure of the...

TipRanks 21h
Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’

After Sarepta (SRPT) competitor Novartis (NVS) reported that its Phase 3 HARBOR trial of del-desiran in myotonic dystrophy type 1 failed to achieve statistical...

Benzinga 21h
QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000

Amgen Inc. (NASDAQ:AMGN) cratered 9.8% to $394.56 Tuesday, on track for its worst single-day loss since October 2000. The damage came from a rival. Novartis A...

QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000
TipRanks 22h
H.C. Wainwright reiterates Sell on Sarepta after Novartis study miss

H.C. Wainwright reiterates a Sell rating on Sarepta (SRPT) with a $5 price target after Novartis (NVS) said its Phase 3 study of del-desiran missed its placebo-...

MarketWatch 1d
Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff

A major clinical-trial failure last week is rippling across biopharma stocks on Tuesday morning, showing yet again how risky it is to invest in drug development...

Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff
TipRanks 1d
Morning Movers: Novartis slumps after HARBOR study misses primary endpoint

The S&P is pointed toward a weaker open as a renewed jump in oil prices and escalating Middle East tensions revive inflation concerns. Brent crude has climbed t...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.